CA2585490A1 - Composes heteroaromatiques de l'azote qui se lient au site actif d'enzymes de type proteines kinases - Google Patents

Composes heteroaromatiques de l'azote qui se lient au site actif d'enzymes de type proteines kinases Download PDF

Info

Publication number
CA2585490A1
CA2585490A1 CA002585490A CA2585490A CA2585490A1 CA 2585490 A1 CA2585490 A1 CA 2585490A1 CA 002585490 A CA002585490 A CA 002585490A CA 2585490 A CA2585490 A CA 2585490A CA 2585490 A1 CA2585490 A1 CA 2585490A1
Authority
CA
Canada
Prior art keywords
alkyl
aryl
heteroaryl
alkoxy
nr4r5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002585490A
Other languages
English (en)
Inventor
Veronique Birault
Jose Antonio Bravo
Roger Crossley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0425026A external-priority patent/GB0425026D0/en
Application filed by Individual filed Critical Individual
Publication of CA2585490A1 publication Critical patent/CA2585490A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA002585490A 2004-11-12 2005-11-11 Composes heteroaromatiques de l'azote qui se lient au site actif d'enzymes de type proteines kinases Abandoned CA2585490A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0425026A GB0425026D0 (en) 2004-11-12 2004-11-12 Compounds which bind to the active site of protein kinase enzymes
GB0425026.2 2004-11-12
GBGB0500245.6A GB0500245D0 (en) 2004-11-12 2005-01-07 Compounds which bind to the active site of protein kinase enzymes
GB0500245.6 2005-01-07
PCT/GB2005/004358 WO2006051311A1 (fr) 2004-11-12 2005-11-11 Composés hétéroaromatiques de l'azote qui se lient au site actif d'enzymes de type protéines kinases

Publications (1)

Publication Number Publication Date
CA2585490A1 true CA2585490A1 (fr) 2006-05-18

Family

ID=35788166

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002585490A Abandoned CA2585490A1 (fr) 2004-11-12 2005-11-11 Composes heteroaromatiques de l'azote qui se lient au site actif d'enzymes de type proteines kinases

Country Status (4)

Country Link
EP (1) EP1814856A1 (fr)
JP (1) JP2008519814A (fr)
CA (1) CA2585490A1 (fr)
WO (1) WO2006051311A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
CA2660560A1 (fr) * 2006-08-16 2008-02-21 Boehringer Ingelheim International Gmbh Composes de pyrazine, leur utilisation et procedes de preparation
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
GEP20125379B (en) 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
WO2009026276A1 (fr) 2007-08-22 2009-02-26 Irm Llc Composés et compositions de 5- (4- (haloalkoxy) phényl) pyrimidine-2-amine utilisés comme inhibiteurs de kinases
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
MX2011012198A (es) 2009-05-15 2011-12-08 Novartis Ag Aril-piridinas como inhibidoras de sintasa de aldosterona.
JP6041671B2 (ja) * 2009-06-12 2016-12-14 アビバックス ガンを治療する為に有用な化合物
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
PL2531492T3 (pl) 2010-02-05 2016-10-31 Pochodne 1,2,4-triazyno-4-aminy
JP5605727B2 (ja) * 2010-04-06 2014-10-15 Ｊｎｃ株式会社 セレンテラジン類縁体及びセレンテラミド類縁体
BR112013004766A2 (pt) 2010-08-27 2016-08-02 Gruenenthal Gmbh 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
EP2609086B1 (fr) 2010-08-27 2015-02-25 Grünenthal GmbH 2-oxo- et 2-thioxo-dihydroquinoléine-3-carboxamides substitués comme modulateurs de kcnq2/3
TWI522349B (zh) 2010-08-27 2016-02-21 歌林達股份有限公司 作為ｋｃｎｑ２／３調節劑之被取代之２－氧基－喹啉－３－甲醯胺
BR112013005056A2 (pt) 2010-09-01 2016-05-31 Gruenenthal Gmbh 1-oxo-di-hidroisoquinolina-3-carboxamidas substituídas como moduladores kcnq2/3
EA201390717A1 (ru) * 2010-11-17 2013-10-30 Новартис Аг 3-(аминоарил)пиридиновые соединения
WO2013126608A1 (fr) * 2012-02-22 2013-08-29 Sanford-Burnham Medical Research Institute Composés sulfonamides et leurs utilisations en tant qu'inhibiteurs de tnap
EP2757161A1 (fr) 2013-01-17 2014-07-23 Splicos miRNA-124 comme biomarqueur de l'infection virale
EP3626245B1 (fr) * 2013-04-24 2021-05-05 Kyushu University, National University Corporation Agent thérapeutique pour maladie du fond de l'oeil
WO2015108861A1 (fr) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
WO2015108881A1 (fr) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
EP2974729A1 (fr) 2014-07-17 2016-01-20 Abivax Dérivés de quinoléine utilisés dans le traitement de maladies inflammatoires
WO2017007755A1 (fr) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
EP4088719A1 (fr) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Procédés et compositions pharmaceutiques pour le traitement de non-perfusion capillaire rétinienne
US12048761B2 (en) 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
MX2019008302A (es) 2017-01-11 2019-12-02 Rodin Therapeutics Inc Inhibidores biciclicos de histona desacetilasa.
MX2020001484A (es) 2017-08-07 2020-08-20 Rodin Therapeutics Inc Inhibidores bicíclicos de la histona desacetilasa.
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3669873A1 (fr) 2018-12-20 2020-06-24 Abivax Dérivés de quinoline destinés à être utilisés dans le traitement de maladies inflammatoires
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
KR20220064369A (ko) 2019-08-14 2022-05-18 인사이트 코포레이션 Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024119067A1 (fr) 2022-12-02 2024-06-06 Neumora Therapeutics, Inc. Méthodes de traitement de troubles neurologiques
WO2024159284A1 (fr) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Hydrazides inhibiteurs de nav 1.7 et/ou de nav 1.8, leurs procédés d'obtention, compositions, utilisations, méthodes de traitement et trousses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60023926T2 (de) * 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
DK1330452T3 (da) * 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
US7122550B2 (en) * 2002-05-23 2006-10-17 Cytopia Pty Ltd Protein kinase inhibitors
JP2007516196A (ja) * 2003-07-02 2007-06-21 ガラパゴス エヌブイ Ｒｈｏキナーゼ阻害剤としてのピラジン及びピラリジン誘導体

Also Published As

Publication number Publication date
WO2006051311A1 (fr) 2006-05-18
EP1814856A1 (fr) 2007-08-08
JP2008519814A (ja) 2008-06-12

Similar Documents

Publication Publication Date Title
CA2585490A1 (fr) Composes heteroaromatiques de l'azote qui se lient au site actif d'enzymes de type proteines kinases
EP1644365A2 (fr) Composes se liant au site actif d'enzymes proteine kinases
TWI377198B (en) Novel pyridine derivatives and pyrimidine derivatives (3)
TWI338684B (en) Tetrahydroquinoline derivatives and a process for preparing the same
US20080194584A1 (en) Nitrogen Heteroaromatic Compounds Which Bind To The Active Site Of Protein Kinase Enzymes
US20060199821A1 (en) Heterocyclic amides and sulfonamides
TW200526635A (en) Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
TW201704237A (zh) 適用於治療與ｋｉｔ及ｐｄｆｇｒ相關之病症的組合物
KR20130109943A (ko) 항암 및 항증식 활성을 나타내는 시클로프로필 디카르복사미드 및 유사체
JP7195436B2 (ja) バニン阻害剤としての複素芳香族化合物
KR20070026357A (ko) 인돌 유도체, 및 키나제 억제제, 특히 ｉｋｋ2억제제로서의 그의 용도
AU758246B2 (en) N,N-substituted cyclic amine derivatives
WO2018121650A1 (fr) Inhibiteur de fgfr
JP5412430B2 (ja) ｍＧｌｕ５拮抗薬としての新規複素環系化合物
Hobson et al. Identification of selective dual ROCK1 and ROCK2 inhibitors using structure-based drug design
CN111620878A (zh) 吡咯并嘧啶类衍生物作为蛋白激酶抑制剂及其应用
WO2006072792A2 (fr) Composes se liant au site actif des proteines kinases
SK6862003A3 (en) Guanidine and amidine derivatives as factor XA inhibitors, process for the preparation thereof, pharmaceutical composition and use thereof
EP2733144B1 (fr) Nouveau composé ayant une activité d'inhibition de parp
US20090163515A1 (en) Compounds Which Bind to the Active Site of Protein Kinase Enzymes
KR100791693B1 (ko) 항혈전제 및 항응고제로서의 ｎ-(헤테로시클릴)벤젠 또는피리딘 술폰아미드
TW201619134A (zh) 取代苯基化合物
US11078161B2 (en) Rock-inhibiting compound and uses thereof
CN116891464A (zh) 一种at2r激动剂
AU2004218180B2 (en) Novel aminopyridine derivatives as mGluR5 antagonists

Legal Events

Date Code Title Description
FZDE Dead